A single rogue protein, present in nearly every person diagnosed with amyotrophic lateral sclerosis, has long been the focus of intense scientific pursuit and a major roadblock to effective treatment. Netherlands-based biotechnology company VectorY Therapeutics has now initiated a landmark clinical
The emergence of cell-cultured protein has sparked intense debate at the intersection of agricultural tradition and technological innovation, nowhere more so than in states with deep roots in the livestock industry. In South Dakota, a legislative effort to completely prohibit the sale of lab-grown
Beijing Huaguan Biotechnology Co., Ltd., a pioneering force in synthetic biology and green chemical manufacturing, has officially closed its Series C financing round, securing hundreds of millions of RMB to accelerate its growth trajectory. This substantial capital infusion was driven by a
In a move that sends ripples across the global pharmaceutical landscape, AstraZeneca has committed to a landmark $15 billion investment in China, a strategic initiative designed to run through 2030. The announcement, made on January 29, 2026, signals a profound deepening of the company's research,
For decades, the path from a promising antibody discovery in the lab to a life-saving therapy for patients has been fraught with uncertainty. Many drugs that show incredible potential in early tests ultimately fail in human trials, costing billions and delaying medical progress. Today we're
Researchers have developed a groundbreaking microfluidic chip using a single-step 3D printing process that successfully mimics the three-dimensional environments where cells grow in the human body, a development poised to revolutionize how diseases are studied and new drugs are tested. This new
